Academia.edu no longer supports Internet Explorer.
To browse Academia.edu and the wider internet faster and more securely, please take a few seconds to upgrade your browser.
…
7 pages
1 file
The incidence of acute kidney injury (AKI) is increasing and is associated with increased morbidity and mortality. AKI is now recognized as a risk factor for progressive chronic kidney disease (CKD). Additionally, patients with CKD are at increased risk for development of AKI due to structural and functional abnormalities, comorbidities, need for invasive procedures and multiple medications. Patients with rapid progression to end-stage renal disease (ESRD) often have courses marked by decline in kidney function due to one or more episodes of AKI. It is important to identify and counsel patients at risk for AKI and to employ risk reduction measures prior to the development of AKI. A rapid assessment for reversible cause of AKI should occur, especially in patients with CKD and treatment aimed at timely optimization of volume and hemodynamic status should be pursued. Early consultation with a nephrologist is indicated if the cause is not immediately clear, evidence of progressive AKI or the complications emerge, or if a tissue diagnosis is required. Finally, patients who experience AKI should be followed for the resolution of AKI and evaluated for development or progression of complications. The key elements in any AKI prevention and management strategy, whenever feasible, are optimization of hemodynamics, correction of fluid and electrolyte imbalances, discontinuation of nephrotoxic drugs, dose adjustment of administered medications and avoidance of contrast media.
Clinical Decisions in Nephrology, Hypertension and Kidney Transplantation, 2012
Acute kidney injury is common in hospitalized children and is associated with siginficant morbidity and mortality especially in critically ill children. A complete evaluation is necessary for all children with AKI as early recognition and treatment is paramount. Apart from clinical evaluation, urinalysis, biochemical investigations and imaging studies helps in the diagnosis of the specific cause of AKI and assessing its severity. Attention should be given to assessment of volume status and fluid administration because volume depletion is a common and modifiable risk factor for AKI. Prevention or prompt management of complications like fliud overload, hyperkalemia and metabolic acidosis improves outcomes. Immediate initiation of renal replacement therapy (RRT) is indicated in the presence of life threatening changes in fluid, electrolyte and acid-base balance. Other measures like treating the underlying cause of AKI, adapting dosage of drugs to renal function, treatment of infections and providing adequate nutrition is important. Children with AKI should be followed up as they are at risk for development of chronic kidney disease.
Basic Nephrology and Acute Kidney Injury, 2012
Acute kidney injury (AKI), impairment of kidney function requires special attention in intensive care unit's (ICU), because if multiorgan failure affect the kidney, it carries a greater risk for worse outcome and furthermore survivors have higher risk then normal population for chronic renal failure. It was reported that they also have higher mortality and morbidity rates compared to normal population (Kellum, 2008 & Shiffle, 2006). Acute tubular necrosis (ATN) is the primary causes of AKI in hospital and ICU and sepsis, ischemic or toxic insults were reported as the most common reason for ATN. The rates of AKI have been reported in hospitalized patients to be between 3.2%-20% and in ICUs this rate rises up to 22% and even to 67% depending on the population studied and the definition used (Murugan 2011). Based on the administrative data, the incidence of severe AKI (defined requiring dialysis) from 1988 to2002 has increased from 4 to 27 per 100000 population. But fortunately in hospital mortality, has decreased from 41.3 to28 % (p<0.001) (Waikar, 2008). Likewise a progressive 2.8% annual increase in incidence of AKI and progressive 3.8% annual decrease in AKI associated mortality(95%CI:-4.7 to-2.12:p<0.001) was observed from 1996-2005 in a large database in Australia and New Zealand (Pisoni, 2008&Bagshaw, 2007). Despite the fact that mortality might be decreasing in ICU patients with AKI, it is still high and reported to be up to 43-88%. Mortality rate becomes even higher when patients require renal replacement therapy (Kellum, 2008). Interestingly, it was reported that irreversible AKI requiring chronic dialysis therapy increased from 3.7% in 1984 to 18.2% in 1995 in surviving patients. Even higher number of patients (33-68%) at discharge whose kidney failed to recover and who needed long term dialysis. This changing renal outcome in the survivors of ICU acquired AKI cases might be related to increasing number of older patients, several co morbid conditions, more severe AKI cases than before and in addition, complication of the more aggressive renal replacement therapies currently used (Shiffle, 2006). Since AKI in critical ill patients have high mortality rate and even if patients survive, they are at risk for End Stage Renal Disease (ESRD) and higher mortality than the normal population, it is important to recognize the clinical picture of AKI and to institute prevention as early as possible. Thus, physician should be alarmed and be ready for early intervention in this particular group of patients. With the introduction of the RIFLE
Clinical Journal of the American Society of Nephrology, 2008
The evaluation and initial management of patients with acute kidney injury (AKI) should include: (1) an assessment of the contributing causes of the kidney injury, (2) an assessment of the clinical course including comorbidities, (3) a careful assessment of volume status, and (4) the institution of appropriate therapeutic measures designed to reverse or prevent worsening of functional or structural kidney abnormalities. The initial assessment of patients with AKI classically includes the differentiation between prerenal, renal, and postrenal causes. The differentiation between so-called "prerenal" and "renal" causes is more difficult, especially because renal hypoperfusion may coexist with any stage of AKI. Using a modified Delphi approach, the multidisciplinary international working group, generated a set of testable research questions. Key questions included the following: Is there a difference in prognosis between volume-responsive and volume-unresponsive AKI? Are there biomarkers whose patterns (dynamic changes) predict the severity and recovery of AKI (maximal stage of AKI, need for RRT, renal recovery, mortality) and guide therapy? What is the best biomarker to assess prospectively whether AKI is volume responsive? What is the best biomarker to assess the optimal volume status in AKI patients? In evaluating the current literature and ongoing studies, it was thought that the answers to the questions posed herein would improve the understanding of AKI, and ultimately patient outcomes.
Primary care, 2014
Acute kidney injury (AKI) is becoming more prevalent in the hospital setting and is associated with the worst prognostic outcomes, including increased mortality. Many different factors contribute to the development of AKI in hospitalized patients, including medications, older age, sepsis, and comorbid conditions. Correct evaluation and management of AKI requires investigation and understanding of important causative factors for each of the 3 pathophysiologic categories of renal failure. Preventative efforts rely on prompt recognition of AKI while avoiding iatrogenic insults in the hospital setting.
Clinics in Chest Medicine, 2009
Acute kidney injury (AKI) is a common clinical syndrome with a broad aetiological profi le. It complicates about of hospital admissions and of admissions to intensive care units (ICU). During last years has been a signifi cant change in the spectrum of severe AKI such that it is no longer mostly a single organ phenomenon but rather a complex multisystem clinical problem. Despite great advances in renal replacement technique (RRT), mortality from AKI, when part of MOF, remains over . e changing nature of AKI requires a new approach using the new advanced technology. Clinicians can provide therapies tailored to time constraints (intermittent, continuous, or extended intermittent), haemodynamic, and metabolic requirements and aimed at molecules of variable molecular weight.
Anaesthesia Critical Care & Pain Medicine, 2016
Acute kidney injury (AKI) is a syndrome that has progressed a great deal over the last 20 years. The decrease in urine output and the increase in classical renal biomarkers, such as blood urea nitrogen and serum creatinine, have largely been used as surrogate markers for decreased glomerular filtration rate (GFR), which defines AKI. However, using such markers of GFR as criteria for diagnosing AKI has several limits including the difficult diagnosis of non-organic AKI, also called "functional renal insufficiency" or "pre-renal insufficiency". This situation is characterized by an oliguria and an increase in creatininemia as a consequence of a reduction in renal blood flow related to systemic haemodynamic abnormalities. In this situation, "renal insufficiency" seems rather inappropriate as kidney function is not impaired. On the contrary, the kidney delivers an appropriate response aiming to recover optimal systemic physiological haemodynamic conditions. Considering the kidney as insufficient is erroneous because this suggests that it does not work correctly, whereas the opposite is occurring, because the kidney is healthy even in a threatening situation. With current definitions of AKI, normalization of volaemia is needed before defining AKI in order to avoid this pitfall.
Acute kidney injury (AKI) is an independent risk factor for morbidity and mortality. This review provides essential information for the diagnosis and management of AKI. Blood urea nitrogen and serum creatinine are used for the diagnosis of AKI. The review also focuses on recent studies on the diagnosis of AKI using the RIFLE (R-renal risk, I-injury, F-failure, L-loss of kidney function, E-end stage kidney disease) and Acute Kidney Injury Network criteria, and serum and urine AKI biomarkers. Dialysis is the only Food and Drug Administration-approved therapy for AKI. Recent studies on the dose of dialysis in AKI are reviewed.
Nephrology, 2018
There is an imminent need to increase awareness among general physicians about the long term risk of an episode of AKI and the improved outcomes with early referral and follow up by a nephrologist. This review highlights the importance of recognising the renal and non-renal consequences following an episode of AKI, and the available biomarkers for this condition. LONG-TERM SYSTEMIC CONSEQUENCES OF AKI Patients surviving an episode of AKI are at an increased risk of death. This was observed in the extended follow-up
Loading Preview
Sorry, preview is currently unavailable. You can download the paper by clicking the button above.
Anwer Khan Modern Medical College Journal, 2017
Anaesthesia and Intensive Care, 2012
Journal of Critical …, 2010
Journal of Clinical Medicine
Canadian Journal of Anesthesia/Journal canadien d'anesthésie, 2012
Clinical Medicine, 2014
TEXILA INTERNATIONAL JOURNAL OF CLINICAL RESEARCH, 2016
Primary Care: Clinics in Office Practice, 2008
Nephron Clinical Practice, 2011
2010
The journal of the Royal College of Physicians of Edinburgh
Nephrology Dialysis Transplantation, 2014
Nephrology Dialysis Transplantation, 2014
Prilozi / Makedonska akademija na naukite i umetnostite, Oddelenie za biološki i medicinski nauki = Contributions / Macedonian Academy of Sciences and Arts, Section of Biological and Medical Sciences, 2008